A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond

Authors

Marcus S Noel, Georgetown Lombardi Comprehensive Cancer Center
Semmie Kim, TYME Technologies Inc.
Marion L Hartley, The Ruesch Center for the Cure of Gastrointestinal Cancers
Steve Wong, Sarcoma Oncology Research Center
Vincent J Picozzi, Virginia Mason Hospital and Medical Center
Harry Staszewski, Mather Hospital
Dae Won Kim, The University of Texas MD Anderson Cancer Center
Jan M Van Tornout, TYME Technologies Inc.
Philip Agop Philip, Wayne State University
Vincent Chung, City of Hope
Allyson J Ocean, Weill Cornell Medical College
Andrea Wang-Gillam, Washington University School of Medicine in St. Louis

Journal

Cancer Medicine

Publication Date

11-1-2022

Volume

11

Issue

22

First Page

4169

Last Page

4181

Document Type

Open Access Publication

DOI

10.1002/cam4.4768

Rights and Permissions

Noel, MS, Kim, S, Hartley, ML, et al. A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond. Cancer Med. 2022; 11: 4169- 4181. doi: 10.1002/cam4.4768 © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Noel, Marcus S; Kim, Semmie; Hartley, Marion L; Wong, Steve; Picozzi, Vincent J; Staszewski, Harry; Kim, Dae Won; Van Tornout, Jan M; Philip, Philip Agop; Chung, Vincent; Ocean, Allyson J; and Wang-Gillam, Andrea, "A randomized phase II study of SM-88 plus methoxsalen, phenytoin, and sirolimus in patients with metastatic pancreatic cancer treated in the second line and beyond." Cancer Medicine. 11, 22. 4169 - 4181. (2022).
https://digitalcommons.wustl.edu/oa_4/692